Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19 Booster Vaccination in MS
NCT05081271Phase 1Terminated
- Sponsor
- Griffin Hospital
- Start
- Oct 2021
- Primary completion
- May 2022
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tozinameran, elasomeran and Ad26.COV2.S in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Griffin Hospital. Primary endpoint: Percent who test positive for COVID-19 spike protein antibodies following booster. Started Oct 2021; status: terminated.
02
Drugs
tozinameranelasomeranAd26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05081271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05081271.